We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Biocompatibles | LSE:BII | London | Ordinary Share | GB00B0L2JD04 | ORD 21 53/94P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 429.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 429.00 | GBX |
Biocompatibles (BII) Share Charts1 Year Biocompatibles Chart |
|
1 Month Biocompatibles Chart |
Intraday Biocompatibles Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/3/2011 | 14:22 | BII - Please tell me why I shouldn't do it? | 33 |
| 26/1/2011 | 15:08 | Biocompatibles: Heading for a Rise? | 385 |
| 27/9/2005 | 12:40 | Where to now for Biocompatibles? | 216 |
| 22/4/2003 | 11:23 | BIOCOMPATIBLES WINS US FDA APPROVAL!!! | 66 |
| 06/1/2003 | 09:47 | Biocompatibles - Moves up on hopes of regulatory approval | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 26/1/2011 06:43 by spyder Goodbye BII ....I believe that today is the last day of dealings for BII, it is a sad day in many respects, but one that has come about as a result of good news. I see that the shares are up 74% year on year, not a bad result to say the least. I have been with these shares since 1995 and what a wild ride it has been, scaling the peaks above £14 and depths of 70p, but I am pleased to have settled at £4 with a significant amount of cash back along the way and even a couple of dividends. There are very few biotech / medtech companies that can compare to BII with the vast majority performing like dogs, and believe me I know as at one time or another I have held a few of them! Investing in shares is a never ending learning curve, but the one thing the BII has taught me is to stick with sensible, reliable, intelligent and consistent management and avoid overenthusiastic, unrealistic management that seem to move through the sector as if on a conveyor belt, destroying shareholder value as they pass through. Hats off to CS and IA in particular for keeping BII on the straight and narrow path to success which has happily / sadly but inevitably lead us into the arms of another. |
Posted at 08/12/2010 09:42 by tratante Think its just tracking btg share price |
Posted at 07/12/2010 19:37 by fenners66 Any rumours of a counter bid?Share price rising again ? |
Posted at 21/11/2010 18:46 by baronet 1 In furtherance of the above :-Questor share tip: --- Take up BTG's offer for Biocompatibles Questor recommended buying shares in Biocompatibles because it was a very unusual beast a biotechnology company that was profitable and paying a dividend. Now BTG want to buy the company. By Garry White 7:00AM GMT 21 Nov 2010 Comments Biocompatibles 391p Questor says TAKE UP OFFER On Friday, it was revealed that BTG, the maker of an experimental varicose vein treatment called Varisolve, had agreed to buy the company. The company offered 1.6733 new BTG shares and 10p in cash for each share in Biocompatibles. The announcement valued this offer at 430p a share, but BTG shares moved lower after the announcement and, based on BTG's closing price on Friday, this values the offer at 397½p. The deal will expand BTG's commercial infrastructure in the US and gives it access to Biocompaibles' major product "drug-eluting bead technology" which can be implanted in the body to block blood supply to areas of disease, and can be used to deliver drugs to a specific organ or tissue. Biocompatibles shares were recommended at 270p on September 16 this year and the bid values the shares 47pc above this level. Questor recommends that investors take up the offer from BTG and will give a view on the prospects for BTG shares at a later date. JB |
Posted at 21/11/2010 18:40 by spyder I think this is an excellent deal for both BII and BTG shareholders, it looks like one of those rare win-win situations to me. The market appeared to warm to the idea later in the day on Friday with the share prices ticking up in tandem. Questor in the Sunday Telegraph today recommends that BII shareholders take-up the BTG shares, presumably rather than selling in the market. I think the CVN option is a brilliant idea and I will certainly be electing for it rather than the cash, if nothing else, just for a bit of fun and the sentimental value of holding on to the last piece of BII (even if it was from Cellmed!) In response to the Q above about what will happen to BII's directors, reading the announcement, it gives the impression that the CEO and FD will only have a short term contract with BTG in order to facilitate a smooth transition. If this is the case, that would be a great shame in my opinion as both have contributed to the exceptionally well managed product portfolio development and the prudent fiscal management of BII and would be an asset to any business. I think with >50% irrevocable undertakings from BII shareholders, a counter bid is extremely unlikely if not impossible, but I suspect if there was anyone else interested, they would already have made their presence known, they have had plenty of notice after all! I will be very sad to see the old BII go however. spyder |
Posted at 19/11/2010 15:47 by waterloo01 14:02, Friday 19 November 2010LONDON (ShareCast) - KBC (038460.KQ - news) is impressed with BTG (LSE: BGC.L - news) 's latest acquisition, as it foresees some exposure in emerging markets for the UK drugs group. The acquisition of stent specialist Biocompatibles (BII) is expected to bring in a £36m revenue stream, a significant cash position of £33m and an underlying profitable business (BII reported a £1.2m net profit at interims). Cuddon says that the potential synergies, increased critical mass in the US and the diabetes program partnered with AstraZeneca (LSE: AZN.L - news) is likely to see its valuation rise to outperform "our blue sky target of 600p on a three-year view". For now, the broker recommends 'buy' with a target price of 312p. |
Posted at 19/11/2010 14:18 by tratante isn't there going to have to be an adjustment in BTG share price to account for the shares issued for the BII shares? Won't that push BTG share price down in short term? I don't think BTG holders should be unhappy, they are getting an excellent company in the form of BII. I don't know much about BTG not sure whether to hold or sell. What do people think? |
Posted at 21/9/2010 11:02 by baronet 1 STOCKS NEWS EUROPEBiocompatibles up on bid approach 21 September 2010 09:44:52 Shares in UK smallcap medical technology company Biocompatibles BII.L rise around 12 percent after it confirms a bid approach, having noted recent moves in its share price. The firm is "attractive as a takeover candidate, having established market traction and momentum with its drug eluting bead franchise and some interesting projects in the pipeline," analysts at Nomura say in a note. Biocompatibles is expected to post a maiden profit this year, they say, and a potential acquirer would need to offer a significant premium to Nomura's end-2010 fair value for the stock of 333 pence a share. Possible suitors include Terumo Corp 4543.T , Angiodynamics ANGO.O , SciClone Pharmaceuticals SCLN.O or BTG BGC.L , they add. JB |
Posted at 21/9/2010 06:31 by spyder Wow - I didn't see that coming!!It is a curious statement as it rather implies that the 'recent movement in the share price' is related to the offer, whereas, as naive as this might sound, I don't think there is any insider connection at all. This might be a rash statement, but as has been observed above, the recent rise was triggered by a buy recommendation from DT's Questor (connected to the bid? Unlikely ...) and has been on the back of extremely thin volumes of just a few thousand shares a day. Furthermore, this is an extremely well run company with a very high regard for corporate governance, social responsibility and fair treatment of all stakeholders. I think the only likely connection between the rise and the bid is that it has flushed out a lurking predator who was waiting for an opportune moment to pounce and saw the price moving against them. For what it is worth, I think any offer must start with a 5 ... |
Posted at 25/3/2010 15:47 by raymund Tratante,Some furter info to assist, I emailed BII last night asking what was going on and received a very helpful and prompt reply before 10.00 am, full marks to BII looking after its' PIs! After the first flash of blue this morning, I went back in early myself at 218.6p and subsequently opened SHARES magazine today to find BII BUY at 235p, so I am well pleased. `Clearly, BII has been greatly oversold (Edison have BII DCF valuation of 390p based on sales growth) and there has been a seller unwinding his position. The BII response to me follows: Thanks for your interest in and support for Biocompatibles. We too have been disappointed with the price performance following the results and have been told that it is due to a couple of reasons: 1. There appears to be a seller who came in ahead of the results and is now unwinding his position into a thin market. Our broker thinks that the position is now unwound fully. We appear to have come back positively this morning following yesterday's recent low. 2. Sentiment towards the sector is also very weak at the moment after a number of disappointments in the last few days (Vectura, Vernalis, Ark) We take our disclosure obligations seriously and there is nothing that we need to inform the market about. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
